Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has entered into a five-year strategic partnership with Sichuan Biopharmaceutical Industry Group Pharmaceutical Industry Group Co., Ltd and Sichuan Development Leading Capital Management Co., Ltd. The collaboration aims to pool resources and leverage mutual strengths to advance the biologics and vaccine sectors in Sichuan province. Financial specifics of the agreement were not disclosed.
The partnership will focus on the expansion of innovative vaccine technology pathways, with an emphasis on research and development in mRNA technology platforms, recombinant protein nanoparticle technology, multivalent vaccines, and novel adjuvant systems. The companies plan to establish a vaccine reserve and a rapid response mechanism within the province, license advanced vaccine production technologies and processes from domestic and international sources, and incubate cutting-edge biotechnologies through relevant science and technology innovation funds. Additionally, the partners will focus on cultivating high-end talent in the field. – Flcube.com
